Drug companies like Eli Lilly and Roche are racing to build supercomputers to help fix the 90% failure rate in drug ...

Eli Lilly’s first-quarter report gave Wall Street another reason to stay optimistic about one of the market’s biggest ...

Doctors say they are alarmed by the number of patients they see injecting themselves with a black market, experimental weight ...

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

After just a few weeks on the market, thousands are already on Foundayo, Eli Lilly's oral weight loss pill. The drugmaker is ...

Americans' voracious appetite for GLP-1 weight loss drugs has the nation on pace to spend more than $1 trillion on ...

High; What We Thought of Eli Lilly’s Earnings. Eli Lilly LLY reported 56% revenue growth and 156% non-GAAP EPS growth in the ...

Revenue tied to Lilly’s Zepbound and Mounjaro more than doubles from the same period last year.

Eli Lilly and Co (NYSE:LLY) reported stronger-than-expected first-quarter 2026 results driven by surging demand for its ...

A federal judge is allowing Eli Lilly & Co. to partially proceed with its lawsuit against a Texas-based pharmacy making copycat versions of its blockbuster obesity and diabetes drugs.

Eli Lilly alleged that Empower lured customers away from their brand-name GLP-1 products and toward the pharmacy's ...

Lilly also clarified that its patented tirzepatide molecule is officially marketed in India under two brand names: Mounjaro ...